3 BioTech Companies To Watch: (ARWR), (AMRI) , & (PWRM)
Arrowhead Research Corporation (NasdaqCM: ARWR)
Change: +$0.06 (+4.88%)
ARWR should be put on a stock alert.
Recent news of Arrowhead's research expecting to raise to $8.7M has brought some interest to their stock. Volume is just under the 3 month average but it's share prices are steadily going up.
Arrowhead Research Corporation identifies advances in nanotechnology and matches them with product development opportunities in high-growth markets, focusing on the electronics and biotech industries. It focuses on developing, commercializing, and licensing a range of nanotechnology products and applications, including anti-cancer drugs, RNAi therapeutics, regenerative therapeutics, advanced drug delivery technology, energy storage technology, carbon-based electronics, and fullerene anti-oxidants.
Arrowhead has developed Cyclosert, a proprietary drug delivery platform technology based on a nano-engineered class of linear cyclodextrin-containing polymers. Its lead anti-cancer drug candidate IT-101 is a combination of Cyclosert and the potent anti-cancer drug, camptothecin, is under Phase I clinical trials. Arrowhead Research also focuses on the design, development, and commercialization of novel RNA interference (RNAi) therapeutics to treat diseases and other medical conditions by combining RNAi therapeutics with patented and proprietary delivery technologies. Its CALAA-01 product is a formulation of proprietary delivery technology with a siRNA duplex targeting the M2 subunit of ribonucleotide reductase.
Albany Molecular Research Inc. (NasdaqGS: AMRI)
Albany Molecular Research Inc. provides scientific services, products and technologies focused on improving the quality of life. The company has steadily evolved, with global facilities now in the United States, Europe and Asia. Its 1,200+ employees have the experience and commitment necessary to provide customers with a wide range of services, technologies and cost models.
AMRI offers drug discovery services, including assay development and design; screening programs, which provide tools to identify active compounds during the lead discovery phases of drug discovery; screening libraries for screening and hit-to-lead programs; bioanalytical services for extraction and quantitation of drug and metabolites in biological fluids and tissues; and natural product services. AMRI performs services including drug discovery, pharmaceutical development, and manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies.
POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)
PWRM is still available for $0.038 cents a share and is continuing creeping closer to 30 RSI, which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.
PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:
Processes - The manner in which the discoveries are made and tests developed
Discoveries - Protein disease footprints,
Products - Early detection tests, Biomarkers, and Drug Targets
The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance:
The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance.
Continue your research at www.power3medical.com
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.StockHotTips.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEpicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
As a community-building service, TMCnet allows user submitted content which is not always proofed by TMCnet editors. If you feel this entry is of inferior quality or wish to report it for some reason, please forward the URL to "webedit [AT] tmcnet [DOT] com" with your comments.
[ Back To Cloud Computing 's Homepage ]